Monte Rosa soars after $5.7 billion drug development deal with Novartis

Monte Rosa Therapeutics

15/09/2025 12:24

** Shares of Monte Rosa Therapeutics GLUE.O jump 39.3% to $6.69 premarket

** Company says it has entered into an agreement to collaborate with Swiss drugmaker Novartis NOVN.S to develop drugs for immune-mediated diseases

** The deal includes an upfront payment of $120 million to Monte Rosa, with the company eligible for a total of up to $5.7 billion in milestones and option payments across programs

** Monte Rosa will also receive tiered royalties on global net sales ranging from high single digits to low double digits

** As of last close, stock down 30.6% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))